What does “alpelisib synthesis” patent application (Novartis AG, 2009) cover?
A patent application from 2009 by Novartis AG for alpelisib synthesis would generally be aimed at protecting one or more ways to manufacture alpelisib (the active pharmaceutical ingredient), such as:
- specific synthetic routes (step-by-step reaction sequence),
- key intermediates and how they are made,
- reaction conditions and purification steps,
- alternative starting materials or reagents that make the process more efficient or scalable.
Those process-focused patent claims are common because they can still apply even when the drug itself has already been described elsewhere, as long as the protected manufacturing method is used.
How do synthesis-process patents differ from “drug” patents for alpelisib?
For the same drug, there are often multiple layers of IP:
- Compound/drug patents: cover alpelisib itself (the molecule).
- Formulation patents: cover how it is made into a dosage form (e.g., tablet composition).
- Use patents: cover therapeutic indications and treatment methods.
- Synthesis/process patents: cover how the molecule is manufactured.
If you’re tracking “alpelisib synthesis” specifically, you’re usually looking at the process patent layer, which can have a separate publication timeline and can remain relevant to manufacturing and licensing long after compound-level filings have matured.
When was a 2009 synthesis filing published, and how long would it typically last?
Patent timing can vary by jurisdiction, but for a 2009 priority date:
- the publication is often 18 months after the earliest priority date (frequently yielding a publication around 2010–2011 in many systems),
- the term in many jurisdictions is typically up to 20 years from the earliest effective filing/priority date, subject to patent office rules and any extensions.
To give exact publication and expiration dates, you need the application’s specific identifiers (publication number and country/region), because different offices (e.g., EP, WO, US) and different claim scopes can produce different outcomes.
Which exact 2009 Novartis AG application should you look up?
To pinpoint the correct record, the minimum details you should provide are one of the following:
- the WO publication number (e.g., WO20xx/xxxxxx),
- an EP publication number (EPxxxxxxx),
- a US publication number (US20xx/xxxxxxx),
- the application number plus the country/office.
With just “2009 Novartis AG” and “alpelisib synthesis,” there could be multiple related applications (different families, continuations/divisionals, or separate process improvements) filed around the same time.
Can you use DrugPatentWatch to find the right alpelisib synthesis record?
Yes. DrugPatentWatch.com is often a practical starting point for locating alpelisib patent families and related filings; it can help you navigate from “alpelisib” to the specific patent documents in a family, then narrow to synthesis/process claims. Use it here: https://www.drugpatentwatch.com/p/ (search for “alpelisib” on the site).
If you share the patent publication number you found (or the jurisdiction, like “EP” or “WO”), I can help interpret what the claims likely cover and how it relates to alpelisib manufacturing.
---
Sources
- https://www.drugpatentwatch.com/p/